Immune reconstitution inflammatory syndrome in natalizumab-associated PML

Neurology

Volumn 77, Issue 11, 2011, Pages 1061-1067

  Tan, I L ^a   McArthur, J C ^a   Clifford, D B ^a   Major, E O ^a   Nath, A ^a  

^a Building 10/7C 103 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOADSORPTION; MALE; MORTALITY; MULTIPLE SCLEROSIS; NEUROIMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES;

EID: 80155208330     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822e55e7     Document Type: Article

References (19)

1. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-370. (Pubitemid 38720991)
2. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)
3. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-824.
4. Carson KR, Even AM, Richey EA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 2009; 113:4834-4840.
5. Bellizi A, Barucca V, Fioriti D, et al. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol Epub 2010 Apr 16.
6. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
7. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha-4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68. (Pubitemid 23008085)
8. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha-4 beta-1 integrin. Nature 1992;356:63-66.
9. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multi- focal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353: 375-381. (Pubitemid 41132342)
10. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374. (Pubitemid 41132341)
11. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368. (Pubitemid 41132340)
12. Clifford DB, DeLuca A, Simpson DA, et al. Natalizumab associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
13. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-1464.
14. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72:402-409.
15. Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009;72:1922-1930.
16. Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through a G-protein coupled receptor. FASEB J 2006;20:1209-1211.
17. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following PML is MS patients treated with natalizumab. Ann Neurol 2010;68:384-391.
18. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341-349. (Pubitemid 28421438)
19. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-1751.